Deucrictibant (PHVS719 XR)

About Pharvaris

Pharvaris is a late-stage biopharma focused on transforming the treatment paradigm for bradykinin-mediated angioedema, particularly hereditary angioedema (HAE), through oral therapies. Its lead asset, deucrictibant, is a novel oral B2 receptor antagonist in pivotal Phase 3 trials for both on-demand and prophylactic treatment of HAE attacks. The company's strategy is to provide patients and physicians with effective, convenient, and well-tolerated oral alternatives to the current standard of injectable therapies, potentially capturing a significant share of the growing HAE market.

Therapeutic Areas